Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Tvardi Therapeutics, Inc. (Name of Issuer) |
Common Stock of Tvardi Therapeutics, Inc. (Title of Class of Securities) |
140755208 (CUSIP Number) |
04/15/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 140755208 |
1 | Names of Reporting Persons
Solas Tvardi Sidecar LLC | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
TENNESSEE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
761,287.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
8.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13G
|
CUSIP No. | 140755208 |
1 | Names of Reporting Persons
Solas BioVentures Fund II, LP | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
761,287.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
8.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
CUSIP No. | 140755208 |
1 | Names of Reporting Persons
Solas Partners II, LLC | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
761,287.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
8.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
Tvardi Therapeutics, Inc. | |
(b) | Address of issuer's principal executive offices:
3 SUGAR CREEK CTR. BLVD., STE 525, SUGAR LAND, TEXAS, 77478 | |
Item 2. | ||
(a) | Name of person filing:
Solas Tvardi Sidecar, LLC Solas BioVentures Fund II, LP Solas Partners II, LLC | |
(b) | Address or principal business office or, if none, residence:
All entities: 412 Georgia Ave., STE 201 Chattanooga, TN 37403 | |
(c) | Citizenship:
Solas Tvardi Sidecar, LLC: Tennessee Solas BioVentures Fund II, LP: Delaware Solas Partners II, LLC: Delaware | |
(d) | Title of class of securities:
Common Stock of Tvardi Therapeutics, Inc. | |
(e) | CUSIP No.:
140755208 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
Please see Row 9 of each Reporting Person's cover page | |
(b) | Percent of class:
Please see Row 11 of each Reporting Person's cover page %
| |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
Please see Row 5 of each Reporting Person's cover page | ||
(ii) Shared power to vote or to direct the vote:
Please see Row 6 of each Reporting Person's cover page | ||
(iii) Sole power to dispose or to direct the disposition of:
Please see Row 7 of each Reporting Person's cover page | ||
(iv) Shared power to dispose or to direct the disposition of:
Please see Row 8 of each Reporting Person's cover page | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Solas Tvardi Sidecar, LLC Solas BioVentures Fund II, LP Solas Partners II, LLC | ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|